Cardiac Science Enhances R&D; Pursues Greater Speed to Market With 3-year Offshore...

Cardiac Science Enhances R&D; Pursues Greater Speed to Market With 3-year
Offshore Design Agreement
Patni to Provide Design and Engineering Support for New Technology Initiatives

BOTHELL, Wash., Sept. 14 /PRNewswire-FirstCall/ -- Cardiac Science Corporation
(Nasdaq: CSCX), a global leader in automated external defibrillator (AED) and
diagnostic cardiac monitoring devices, announced a three-year agreement with
Patni Computer Systems under which Patni will establish a dedicated design
center in India and will expand Cardiac Science's existing in-house design and
development capability.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO)

"One of our strategies is to increase the volume and frequency of new product
introductions, particularly in Cardiac Monitoring. We have great brands and
distribution channels we want to better leverage," said Dave Marver, Cardiac
Science president and chief executive officer. "This agreement provides us the
resources and flexibility to pursue multiple new product development
initiatives simultaneously."

Patni specializes in the design and engineering of Class II and III medical
devices and is a global leader in providing high-quality, reliable, and cost
effective Product Engineering and IT Services. Ajay Chamania, Patni's EVP and
global head of product engineering services, said, "Patni has several years
experience helping companies in the medical device industry reduce time and
cost to market while ensuring complete regulatory compliance. We are thrilled
with the opportunity to do the same for Cardiac Science."

"Our mandate is to increase the speed-to-market while keeping costs in check,"
said Bob Odell, senior vice president of strategy, design, and operations for
Cardiac Science. "This agreement, like the Syncroness relationship we
announced earlier this year, dramatically increases our engineering capacity
and allows internal team members to focus on changing market dynamics, new
customer solutions, and new revenue opportunities."

About Cardiac Science:

Cardiac Science develops, manufactures, and markets a family of advanced
diagnostic and therapeutic cardiology devices and systems, including automated
external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac
stress treadmill and systems, Holter monitoring systems, hospital
defibrillators, cardiac rehabilitation telemetry systems, and cardiology data
management systems (informatics) that connect with hospital information (HIS),
electronic medical record (EMR), and other information systems. The company
sells a variety of related products and consumables and provides a portfolio
of training, maintenance, and support services. Cardiac Science, the successor
to the cardiac businesses that established the trusted Burdick(R),
HeartCentrix(R), Powerheart(R), and Quinton(R) brands, is headquartered in
Bothell, Washington. With customers in more than 100 countries worldwide, the
company has operations in North America, Europe, and Asia. For information,
call 425.402.2000 or visit http://www.cardiacscience.com.

For updates and information on worldwide defibrillation and cardiac
monitoring, find us on the Cardiac Science blog at
http://www.cardiacscience.com/blog, Twitter at
http://twitter.com/cardiacscience, Facebook at http://budurl.com/CSonFB,
YouTube at http://www.youtube.com/user/CardiacScience.

About Patni Computer Systems

Visit http://patni.com for more information on Patni Computer Systems.

Forward-Looking Statements

This press release contains forward-looking statements. The words "believe,"
"expect," "intend," "anticipate," variations of such words, and similar
expressions identify forward-looking statements, but their absence does not
mean that the statement is not forward-looking. Forward-looking statements in
this press release include, but are not limited to, those relating to Cardiac
Science Corporation's expectations regarding cost savings or improved research
and development capabilities and the resulting impact on operating results.
These are forward-looking statements for purposes of the safe harbor
provisions under the Private Securities Litigation Reform Act of 1995. Actual
results may vary significantly from the results expressed or implied in such
statements. Factors that could cause or contribute to such varying results and
other risks are more fully described in Cardiac Science Corporation's Annual
Report on Form 10-K for the year ended December 31, 2008, as updated by
subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation
undertakes no duty or obligation to update the information provided herein.

For more information,
Company Contact: Investor Contact: Media Contact:
---------------- ----------------- --------------
Mike Matysik Matt Clawson Christopher Gale
Cardiac Science Corporation Allen & Caron EVC Group Inc.
Senior Vice President and CFO 949.474.4300 646.201.5431
425.402.2009 matt@allencaron.com 203.570.4681
cgale@evcgroup.com

LOGO: http://www.cardiacscience.com/images/main_logo.gif

CSCX-G

SOURCE Cardiac Science Corporation

Mike Matysik, Senior Vice President and CFO of Cardiac Science Corporation,
+1-425-402-2009; or Investors, Matt Clawson of Allen & Caron, +1-949-474-4300,
matt@allencaron.com; or Media, Christopher Gale of EVC Group Inc.,
+1-646-201-5431, +1-203-570-4681, cgale@evcgroup.com, both for Cardiac
Science Corporation